Results 181 to 190 of about 869,083 (311)

The therapeutic potential of mesenchymal stem cells in intestinal diseases: from mechanisms to clinical translation. [PDF]

Stem Cell Res Ther
Yang JZ, He LY, Lu XZ.
europepmc   +1 more source

New Insights of Biological Functions of Natural Polyphenols in Inflammatory Intestinal Diseases. [PDF]

Int J Mol Sci, 2023
Zhang Y, Mu T, Deng X, Guo R, Xia B, Jiang L, Wu Z, Liu M.   +7 more
europepmc   +1 more source

Intestinal Extract in Rheumatic Diseases [PDF]

Annals of the Rheumatic Diseases, 1947
openaire   +3 more sources

Normal‐Appearing White Matter Injury Mediates Chronic Deep Venous Hypoxia and Disease Progression in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang, Huiying Wang, Zhizheng Zhuo, Ai Guo, Ke Lv, Decai Tian, Chao Chai, Yunyun Duan, Shuang Xia   +8 more
wiley   +1 more source

Evolution of the global burden of vascular intestinal diseases in middle-aged and elderly population: Trend analysis from 1990 to 2021 and projections to 2040. [PDF]

Medicine (Baltimore)
Zhou Z, Zhang T, Shu R, Luo H.
europepmc   +1 more source

Editorial: Engineering probiotics for multiple interventions on intestinal diseases. [PDF]

Front Cell Infect Microbiol, 2023
Huang H, Yin H, Zhang X.
europepmc   +1 more source

Sex Representation in US Stroke Clinical Trials: A Decade of Trends and Challenges

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Stroke remains a major cause of disability and mortality in the US, with significant sex‐based disparities, and females remain underrepresented in stroke clinical trials. We aimed to examine sex representation in US‐based stroke clinical trials, identify trial characteristics associated with higher female enrollment (≥ 50%), and ...
Chaitali Dagli, Mudasir Andrabi, Tova Cohen, Pranali G. Patel, Tapasya Katta, Chen Lin   +5 more
wiley   +1 more source

From Inflammasomes to Pyroptosis: Molecular Mechanisms in Chronic Intestinal Diseases - Opportunity or Challenge? [PDF]

J Inflamm Res
Fang J, Zhu W, Yu D, Zhu L, Zha H, Tang J, Li Y, Zhu X, Zhao T, Zhang W.   +9 more
europepmc   +1 more source

Controversial role of ILC3s in intestinal diseases: A novelty perspective on immunotherapy. [PDF]

Front Immunol, 2023
Zhang Y, Feng X, Chen J, Liu J, Wu J, Tan H, Mi Z, Rong P.   +7 more
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source